Der Diabetologe

, 5:620

Schlaganfallsekundärprävention bei Diabetespatienten

Leitthema
  • 29 Downloads

Zusammenfassung

Patienten mit einem Diabetes mellitus, die eine transitorisch ischämische Attacke oder einen ischämischen Schlaganfall erlitten haben, haben ein erhöhtes Rezidivrisiko für einen erneuten Schlaganfall. Die frühzeitige Initiierung einer nichtmedikamentösen und medikamentösen Sekundärprophylaxe ist daher gerade in dieser Patientengruppe von höchster Bedeutung. Dabei unterscheiden sich die grundsätzlichen Therapieprinzipien nicht bei Schlaganfallpatienten mit oder ohne Diabetes mellitus. Wir geben einen Überblick über die evidenzbasierte, an der Pathophysiologie der zerebralen Ischämie orientierten antithrombotischen Behandlung, die Behandlung mit Antihypertensiva und Statinen sowie den Stellenwert einer intensivierten Blutzuckertherapie in der Schlaganfallsekundärprävention bei Diabetespatienten.

Schlüsselwörter

Sekundärprävention Schlaganfall Transitorisch ischämische Attacke Diabetes mellitus 

Secondary stroke prevention in patients with diabetes mellitus

Abstract

Patients with diabetes mellitus who have suffered a transient ischemic attack or ischemic stroke are at higher risk for a recurrent stroke. Thus, early initiation of non-medical and medical secondary prevention treatment is of major importance in this patient group. The basic principles of stroke prevention are the same in patients with diabetes as in those without. We review the evidence for antithrombotic treatment based on the pathophysiology of ischemic stroke, treatment with antihypertensive and lipid-lowering agents, as well as the significance of intensive blood glucose control in secondary stroke prevention in diabetics.

Keywords

Secondary prevention Stroke Transient ischemic attack Diabetes mellitus 

Literatur

  1. 1.
    Antithrombotic Trialist’s Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 324:71–86CrossRefGoogle Scholar
  2. 2.
    Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7–22CrossRefGoogle Scholar
  3. 3.
    Progress Collaborative Group (2001) Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358:1033–1041CrossRefGoogle Scholar
  4. 4.
    CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329–1339CrossRefGoogle Scholar
  5. 5.
    EAFT (European Atrial Fibrillation Trial) Study Group (1993) Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 342:1255–1262Google Scholar
  6. 6.
    Akins PT, Feldman HA, Zoble RG et al (2007) Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials. Stroke 38:874–880CrossRefPubMedGoogle Scholar
  7. 7.
    Amarenco P, Bogousslavsky J, Callahan A 3rd et al (2006) High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355:549–559CrossRefPubMedGoogle Scholar
  8. 8.
    Bhatt DL, Topol EJ (2004) Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial. Am Heart J 148:263–268CrossRefPubMedGoogle Scholar
  9. 9.
    Chen ZM, Sandercock P, Pan HC et al (2000) Indications for early aspirin use in acute ischemic stroke: A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. Stroke 31:1240–1249PubMedGoogle Scholar
  10. 10.
    Collins R, Armitage J, Parish S et al (2004) Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363:757–767CrossRefPubMedGoogle Scholar
  11. 11.
    Connolly S, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus Warfarin in patients with atrial fibrillation. N Engl J Med 361 [Epub Aug 30]Google Scholar
  12. 12.
    Connolly S, Pogue J, Hart R et al (2006) Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367:1903–1912CrossRefPubMedGoogle Scholar
  13. 13.
    Diener HC, Aichner F, Bode C et al (2008) Primär- und Sekundärprophylaxe der zerebralen Ischämie. In: Diener HC, Putzki N, Berlit P et al (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie. Thieme, Stuttgart New York, S 261–287Google Scholar
  14. 14.
    Diener HC, Bogousslavsky J, Brass LM et al (2004) Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364:331–337CrossRefPubMedGoogle Scholar
  15. 15.
    Diener HC, Cunha L, Forbes C et al (1996) European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143:1–13CrossRefPubMedGoogle Scholar
  16. 16.
    Gerstein HC, Miller ME, Byington RP et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559CrossRefPubMedGoogle Scholar
  17. 17.
    Grundy SM, Cleeman JI, Merz CN et al (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44:720–732CrossRefPubMedGoogle Scholar
  18. 18.
    Halkes PH, Gray LJ, Bath PM et al (2008) Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk. J Neurol Neurosurg Psychiatry 79:1218–1223CrossRefPubMedGoogle Scholar
  19. 19.
    Halkes PH, van Gijn J, Kappelle LJ et al (2006) Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 367:1665–1673CrossRefPubMedGoogle Scholar
  20. 20.
    Law MR, Morris JK, Wald NJ (2009) Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338:b1665CrossRefPubMedGoogle Scholar
  21. 21.
    Patel A, MacMahon S, Chalmers J et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572CrossRefPubMedGoogle Scholar
  22. 22.
    Ray KK, Seshasai SR, Wijesuriya S et al (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373:1765–1772CrossRefPubMedGoogle Scholar
  23. 23.
    Rothwell PM, Giles MF, Chandratheva A et al (2007) Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet 370:1432–1442CrossRefPubMedGoogle Scholar
  24. 24.
    Rothwell PM, Giles MF, Flossmann E et al (2005) A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack. Lancet 366:29–36CrossRefPubMedGoogle Scholar
  25. 25.
    Sacco RL, Diener HC, Yusuf S et al (2008) Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 359:1238–1251CrossRefPubMedGoogle Scholar
  26. 26.
    Weimar C, Diener HC, Alberts MJ et al (2009) The Essen stroke risk score predicts recurrent cardiovascular events: a validation within the REduction of Atherothrombosis for Continued Health (REACH) registry. Stroke 40:350–354CrossRefPubMedGoogle Scholar
  27. 27.
    Wilcox R, Bousser MG, Betteridge DJ et al (2007) Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 38:865–873CrossRefPubMedGoogle Scholar
  28. 28.
    Yusuf S, Diener HC, Sacco RL et al (2008) Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 359:1225–1237CrossRefPubMedGoogle Scholar
  29. 29.
    Yusuf S, Sleight P, Pogue J et al (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 342:145–153CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag 2009

Authors and Affiliations

  1. 1.Neurologische Klinik und PoliklinikUniversität Duisburg-EssenEssenDeutschland

Personalised recommendations